Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.
Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission. Attention should be paid to patients over 65 years of age who have severe underlying diseases (cancer, respiratory diseases, cardiovascular and cerebrovascular diseases, chronic renal failure, autoimmune deficiency diseases, etc.) and have not completed the whole course of vaccine, and such patients often have abnormal oxygen tolerance, that is, a significant decrease in skin finger pulse oxygen saturation (SpO2) can occur after daily activities. Basal SpO2 at admission is often associated with prognosis, but it is difficult to differentiate prognosis from responsiveness to treatment by changes in SpO2 after oxygen therapy is administered clinically. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Survivors | Survivors of COVID-19 induced respiratory failure |
| |
| Nonsurvivors | Nonsurvivors of COVID-19 induced respiratory failure |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| outcome | Other | hospital survivors and nonsurvivors |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Level of Transcutaneous partial pressure of oxygen | Level of Transcutaneous partial pressure of oxygen | up to 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Level of Transcutaneous partial pressure of oxygen/FiO2 | Level of Transcutaneous partial pressure of oxygen/FiO2 | up to 30 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
COVID-19 patients
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jingyuan Xu, M.D. | Contact | 008613851417209 | 13851417209@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Jingyuan Xu, M.D. | Southeast University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Zhongda hospital | Recruiting | Nanjing | Jiangsu | 210000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012131 | Respiratory Insufficiency |
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
Not provided
Not provided
Not provided
Not provided
Not provided
| Subtype of COVID-19 |
| Other |
Different subtype of COVID-19 |
|
| D012141 |
| Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |